A hybrid approach to cardiac resynchronization therapy

Robert L Quigley1

  • 1International SOS Assistance, Inc., Pennsylvania 19053, USA. robert.quigley@internationalsos.com

Insights

Cardiac resynchronization therapy (CRT) can be safely performed as a single procedure in a cardiac operating room, improving patient outcomes and potentially reducing costs. This approach offers an alternative to staged procedures, enhancing efficiency and patient care.

Area of Science:

  • Cardiology
  • Cardiac Surgery
  • Medical Technology

Background:

  • Cardiac resynchronization therapy (CRT) improves heart failure symptoms but is traditionally performed in electrophysiology labs.
  • Percutaneous lead placement failure necessitates a staged surgical approach, increasing length of stay and infection risk.
  • This study aimed to establish CRT as a routine single-stage procedure in a surgical operating room (OR).

Purpose of the Study:

  • To demonstrate the feasibility and efficacy of performing CRT as a single-stage procedure in a cardiac OR.
  • To evaluate outcomes and procedural efficiency compared to traditional staged approaches.
  • To explore the potential benefits of hybrid ORs for complex cardiac interventions.

Main Methods:

  • 18 patients with moderate-severe heart failure and conduction delays underwent CRT in a surgical OR.
  • Procedures involved general anesthesia, arterial lines, and Foley catheters.
  • Nine patients received epicardial left ventricular (LV) leads via mini-thoracotomy; others had transvenous leads.
  • All devices included defibrillation technology (ICD).

Main Results:

  • Successful bi-ventricular pacing was achieved in all 18 patients within an average of 170 minutes.
  • Left ventricular ejection fraction (LVEF) improved by an average of 5% at 1-month follow-up in 14 patients.
  • Mitral regurgitation severity decreased in 4 out of 5 patients.
  • Average length of stay was 4 days for non-thoracotomy cases and 7 days for thoracotomy cases.

Conclusions:

  • CRT can be successfully performed as a single-stage procedure in a cardiac OR.
  • Epicardial LV lead thresholds are comparable to transvenous leads.
  • Performing complex interventions in hybrid ORs supports cost containment and infection control.
Abstract

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Pulse rhythm01:30

Pulse rhythm

Pulse rhythm refers to the pattern of pulsations within specific intervals, offering valuable insights into the regularity or irregularity of the heart's beats as observed through the pattern of pulsation within specific intervals. A regular pulse exhibits a consistent heart rate with uniform waveforms and pulsation force, variations of which can be classified as normal, weak, or bounding.
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac muscle...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...